Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington's Disease
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington's Disease
- Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's disease
- One of Evotec's largest strategic drug discovery alliances
- Evotec和CHDI之間的長期聯盟將有助於治療亨廷頓病
- Evotec最大的戰略藥物發現聯盟之一
HAMBURG, GERMANY / ACCESSWIRE / May 28, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. ("CHDI"). CHDI is a privately funded nonprofit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington's disease. The collaboration will further our fundamental scientific understanding of the disease and thereby aid the development of new effective treatments.
2024年5月28日,德國漢堡 / ACCESSWIRE / Evotec SE(法蘭克福證券交易所:EVT,MDAX/TecDAX,ISIN:DE0005664809;納斯達克:EVO)宣佈延長與CHDI基金會(“CHDI”)長達20年的合作。CHDI是一傢俬人資助的非營利生物醫學研究機構,專門致力於合作開發可以極大地改善受亨廷頓病影響者的生活的治療方案。該合作將進一步促進我們對該疾病基礎科學的理解,從而幫助開發新的有效治療方法。
The collaboration utilises Evotec's integrated neuroscience platform and broad expertise in CNS drug discovery and development. It covers a wide range of biology and chemistry services supported by compound and library management, target validation, stem-cell research, high-content screening, computational chemistry, pharmacology, protein production, and biomarker discovery and validation across multiple sites. Initiated in 2006, the long-standing collaboration is one of the largest strategic drug discovery alliances within Evotec.
該合作利用了Evotec整合的神經科學平台和其在中樞神經系統藥物發現和開發方面的廣泛專業知識。它涵蓋了多個網站的許多生物學和化學服務,包括化合物和文庫管理、靶點驗證、幹細胞研究、高內容篩選、計算化學、藥理學、蛋白質生產,以及生物標記物的發現和驗證。這個長期合作始於2006年,是Evotec內最大的戰略藥物發現合作之一。
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "We are delighted that CHDI recognises the value of our long and highly cooperative relationship. We are tremendously proud of our continued contribution to the fight against Huntington's disease with our colleagues at CHDI, which underscores our unwavering joint commitment to finding new therapies for people affected by this devastating condition."
Evotec的首席運營官克雷格·約翰斯頓博士評論道:“我們很高興CHDI認識到我們長期且高度合作的關係的價值。我們非常自豪能夠與我們在CHDI的同事一起繼續爲抗擊亨廷頓病做出貢獻,這表明我們共同致力於爲受這種破壞性疾病影響的人們尋找新的治療方法。”
Dr Robert Pacifici, Chief Scientific Officer at CHDI, added: "Over the past 20 years, our colleagues at Evotec have been critical to CHDI's preclinical research programs and truly valued scientific allies in our mission to develop therapeutics for people with Huntington's disease. We look forward to continuing our longstanding and productive research collaboration into the foreseeable future."
About Huntington's disease
Huntington's disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent carrying this mutation has a 50-50 chance of inheriting the condition. Due to the presence of the mutation, an individual ́s brain cells undergo failure and subsequent death, resulting in cognitive and physical impairments. These challenges intensify over the course of the disease, significantly impairing the individual's quality of life and ultimately leading to death. Symptoms of Huntington's disease, which generally develop in midlife and become progressively more debilitating over time, can also emerge in infancy or old age. Once overt symptoms start, patients typically live for about 15 to 20 years. Currently, there is no way to delay the onset of symptoms or slow the progression of Huntington's disease. It is estimated that the disorder affects about 30,000 people in the United States, and at least 150,000 others have a 50% risk of developing Huntington's disease at some point.
CHDI的首席科學家羅伯特·帕西菲克博士補充道:“在過去的20年中,我們在Evotec的同事對於CHDI的臨床前研究項目至關重要,是我們開發可以用於治療亨廷頓病的真正值得信賴的科學盟友。我們期待着繼續我們歷史悠久且富有成效的研究合作。”
關於亨廷頓病
亨廷頓病是由huntingtin基因的突變引起的家族性疾病。攜帶該基因突變的父母的每個孩子都有50%的機會繼承該疾病。由於突變的存在,一個人的大腦細胞會出現失敗,並隨後死亡,導致認知和身體功能的受損。這些挑戰隨着疾病的進展而加劇,顯著影響個人的生活質量,最終導致死亡。亨廷頓病的症狀一般在中年時期開始出現,並隨着時間的推移逐漸惡化,也可能在嬰兒期或老年期出現。一旦症狀開始顯現,患者通常可以生存約15至20年。目前,還沒有延緩症狀發作或減緩亨廷頓病進展的方式。據估計,該疾病在美國影響約30,000人,還有至少150,000人有50%的風險在某個時候患上亨廷頓病。
About CHDI Foundation, Inc.
CHDI Foundation is a privately-funded, nonprofit biomedical research organization devoted to a single disease - Huntington's disease. Our mission is to collaboratively develop therapeutics that will substantially improve the lives of those affected by Huntington's disease. To achieve this CHDI manages a diverse portfolio of research projects through a novel virtual model that encourages scientific collaboration to more directly connect innovative research, drug discovery, and clinical development. This helps bridge the translational gap that often exists between academic and industrial research pursuits, and which adds costly delays to therapeutic development. Our activities extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials. To learn more, visit .
關於CHDI基金會
CHDI基金會是一傢俬人資助的非盈利生物醫學研究機構,致力於治療一種疾病—亨廷頓病。我們的使命是合作開發可以極大地改善受亨廷頓病影響者的生活的治療方案。爲了實現這一目標,CHDI管理着一個多樣化的研究項目組合,通過一種新穎的虛擬模型來鼓勵科學研究合作,從而更直接地連接創新研究、藥物發現和臨床開發。這有助於彌合學術和工業研究追求之間經常存在的翻譯鴻溝,併爲治療方案的開發增加了昂貴的延遲。我們的活動從探索性生物學一直延伸到治療靶點的識別和驗證,以及從藥物發現和開發到臨床研究和試驗。要了解更多信息,請訪問 .
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn .
關於Evotec SE
Evotec是一家生命科學公司,擁有獨特的商業模式,致力於發現和開發高效的治療方案,並使其面向患者。該公司的多模式平台包括創新技術、數據和科學,用於發現、開發和生產一流和最佳的製藥產品。Evotec爲所有20大製藥公司和超過800家生物技術公司、學術機構以及其他醫療保健利益相關者提供高價值的管道共同創造夥伴關係和解決方案。Evotec在當前未受關注的廣泛治療領域擁有戰略性的活動,包括神經病學、腫瘤學以及代謝和傳染病。在這些專業領域,Evotec的目標是創建全球領先的共同擁有創新治療方案的管道,並已經建立了從早期發現到臨床開發的200多個自有和共同擁有的研發項目組合。Evotec全球運營,擁有5000多名高素質員工。該公司的17個網站提供高度協同的技術和服務,並作爲卓越的互補集群運作。要了解更多信息,請訪問 並關注我們的X/Twitter @Evotec@Evotec和領英(曾用名Twitter).
Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
前瞻性聲明
SOURCE: Evotec SE
For further information, please contact:
如需更多信息,請聯繫:
Media
媒體
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Gabriele Hansen
全球企業傳媒高級副總裁
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Hinnerk Rohwedder
全球企業傳媒董事
Hinnerk.Rohwedder@evotec.com
Investor Relations
投資者關係
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
Volker Braun
全球投資者關係與esg高級執行副總裁
Volker.Braun@evotec.com
SOURCE: Evotec SE
來源:Evotec SE